The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat Topic 1-Apr-2021: Tell Us What You Want — We’re Listening
- #LCSM Chat Topic 4-Mar-2021: Liquid Bx—It pays to be vein
- #LCSM Chat Topic 4-Feb-2021: “#WCLC20 from the comfort of your own home”
- #LCSM Chat Topic 01/07/2021: What are your predictions for the Rx of #LungCancer in 2021?
- #LCSM Chat Topic 12/03/2020: 2020–Wild Year for #LungCancer
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials COVID-19; antigen test Drugs EGFR epatients immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day